Sökning: onr:"swepub:oai:DiVA.org:liu-162060" >
MRI Assessment of T...
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)
-
- Ajmera, Veeral H. (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Cachay, Edward (författare)
- Univ Calif San Diego, CA 92103 USA
-
- Ramers, Christian (författare)
- Family Hlth Ctr, CA USA
-
visa fler...
-
- Vodkin, Irine (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Bassirian, Shirin (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Singh, Seema (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Mangla, Neeraj (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Bettencourt, Richele (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Aldous, Jeannette L. (författare)
- San Ysidro Hlth, CA USA
-
- Park, Daniel (författare)
- San Ysidro Hlth, CA USA
-
- Lee, Daniel (författare)
- Univ Calif San Diego, CA 92103 USA
-
- Blanchard, Jennifer (författare)
- Univ Calif San Diego, CA 92103 USA
-
- Mamidipalli, Adrija (författare)
- Univ Calif San Diego, CA 92093 USA
-
- Boehringer, Andrew (författare)
- Univ Calif San Diego, CA 92093 USA
-
- Aslam, Saima (författare)
- Univ Calif San Diego, CA 92103 USA
-
- Dahlqvist Leinhard, Olof, 1978- (författare)
- Linköpings universitet,Avdelningen för radiologiska vetenskaper,Medicinska fakulteten,Region Östergötland, Radiofysikavdelningen US,AMRA Med AB, Linkoping, Sweden
-
- Richards, Lisa (författare)
- Univ Calif San Diego Hlth, CA USA
-
- Sirlin, Claude B. (författare)
- Univ Calif San Diego, CA 92093 USA
-
- Loomba, Rohit (författare)
- Univ Calif San Diego, CA 92093 USA
-
visa färre...
-
(creator_code:org_t)
- 2019-06-18
- 2019
- Engelska.
-
Ingår i: Hepatology. - : WILEY. - 0270-9139 .- 1527-3350. ; 70:5, s. 1531-1545
- Relaterad länk:
-
https://www.ncbi.nlm...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) amp;gt;= 5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (+/- standard deviation) of age and body mass index were 48.2 +/- 10.3 years and 30.7 +/- 4.6 kg/m(2), respectively. There was no difference in the reduction in mean MRI-PDFF between the aramchol group at -1.3% (baseline MRI-PDFF 15.6% versus end-of-treatment MRI-PDFF 14.4%, P = 0.24) and the placebo group at -1.4% (baseline MRI-PDFF 13.3% versus end-of-treatment MRI-PDFF 11.9%, P = 0.26). There was no difference in the relative decline in mean MRI-PDFF between the aramchol and placebo groups (6.8% versus 1.1%, P = 0.68). There were no differences in MRE-derived and VCTE-derived liver stiffness and whole-body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end-of-treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. Conclusion: Aramchol, over a 12-week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI-based assessment in patients with HIV-associated NAFLD (clinicaltrials.gov ID:NCT02684591).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ajmera, Veeral H ...
-
Cachay, Edward
-
Ramers, Christia ...
-
Vodkin, Irine
-
Bassirian, Shiri ...
-
Singh, Seema
-
visa fler...
-
Mangla, Neeraj
-
Bettencourt, Ric ...
-
Aldous, Jeannett ...
-
Park, Daniel
-
Lee, Daniel
-
Blanchard, Jenni ...
-
Mamidipalli, Adr ...
-
Boehringer, Andr ...
-
Aslam, Saima
-
Dahlqvist Leinha ...
-
Richards, Lisa
-
Sirlin, Claude B ...
-
Loomba, Rohit
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Hepatology
- Av lärosätet
-
Linköpings universitet